insulin degludec 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4960 844439-96-9

Description:

MoleculeDescription

Synonyms:

  • insulin degludec
  • tresiba
  • NN1250
insulin degludec is a long-acting basal human insulin analog for subcutaneous injection, differs from human insulin in that the amino acid threonine in position B30 has been omitted and a side-chain consisting of glutamic acid and a C16 fatty acid has been attached
  • Molecular weight: 6104.04
  • Formula: C274H411N65O81S6
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 2356.52
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
40 U P
40 U P
40 U P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Sept. 25, 2015 FDA NOVO NORDISK INC
Jan. 21, 2013 EMA
Sept. 28, 2012 PMDA Novo Nordisk Pharma Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 954.29 14.92 371 13730 69477 90544869
Diabetic ketoacidosis 477.22 14.92 169 13932 24238 90590108
Blood glucose increased 417.16 14.92 230 13871 95016 90519330
Blood glucose decreased 218.68 14.92 95 14006 23334 90591012
Diabetes mellitus inadequate control 175.13 14.92 76 14025 18608 90595738
Hyperglycaemia 156.62 14.92 98 14003 50872 90563474
Blood glucose fluctuation 129.67 14.92 43 14058 5040 90609306
Diabetic neuropathy 121.93 14.92 40 14061 4534 90609812
Hypoglycaemic coma 112.42 14.92 34 14067 2956 90611390
Heart sounds 98.82 14.92 25 14076 1119 90613227
Glycosylated haemoglobin increased 97.87 14.92 48 14053 15514 90598832
Prolonged expiration 96.48 14.92 25 14076 1232 90613114
Diabetic retinopathy 81.68 14.92 26 14075 2676 90611670
Sleep disorder due to a general medical condition 72.02 14.92 58 14043 44680 90569666
Hypoglycaemic unconsciousness 71.36 14.92 18 14083 796 90613550
Impaired gastric emptying 70.21 14.92 36 14065 12773 90601573
Depressive symptom 64.64 14.92 26 14075 5259 90609087
Euglycaemic diabetic ketoacidosis 60.63 14.92 26 14075 6175 90608171
Blood glucose abnormal 58.85 14.92 29 14072 9463 90604883
Respiration abnormal 57.46 14.92 27 14074 7936 90606410
Diabetes mellitus 57.13 14.92 60 14041 64815 90549531
Appetite disorder 56.91 14.92 28 14073 9105 90605241
Infusion related reaction 52.76 14.92 3 14098 416777 90197569
Scleroedema 51.32 14.92 10 14091 130 90614216
Stress 50.83 14.92 63 14038 81332 90533014
Rales 47.49 14.92 30 14071 15797 90598549
Suicide attempt 46.50 14.92 58 14043 75341 90539005
Hypoglycaemia unawareness 46.19 14.92 9 14092 117 90614229
Device failure 45.54 14.92 22 14079 6875 90607471
Intentional overdose 45.27 14.92 64 14037 93770 90520576
Ketoacidosis 43.57 14.92 20 14081 5575 90608771
Hypoglycaemic encephalopathy 42.45 14.92 10 14091 331 90614015
Joint abscess 39.60 14.92 10 14091 444 90613902
Acute kidney injury 39.04 14.92 124 13977 320263 90294083
Synovitis 37.18 14.92 4 14097 329748 90284598
Medical device site abscess 36.00 14.92 8 14093 203 90614143
Hospitalisation 35.46 14.92 68 14033 128032 90486314
Medical device site cellulitis 35.46 14.92 8 14093 218 90614128
Arthropathy 35.40 14.92 7 14094 366235 90248111
Ketosis 33.88 14.92 10 14091 799 90613547
Contraindicated product administered 33.39 14.92 5 14096 320134 90294212
Hypoacusis 32.40 14.92 30 14071 27820 90586526
Neuropathy peripheral 32.29 14.92 68 14033 136902 90477444
Retinopathy 31.88 14.92 14 14087 3520 90610826
Fear-related avoidance of activities 31.27 14.92 7 14094 184 90614162
Flank pain 31.09 14.92 25 14076 19197 90595149
Wound 30.99 14.92 5 14096 302975 90311371
Systemic lupus erythematosus 30.89 14.92 9 14092 361887 90252459
Treatment failure 28.96 14.92 6 14095 303922 90310424
Acute painful neuropathy of rapid glycaemic control 28.84 14.92 4 14097 3 90614343
Diabetic metabolic decompensation 28.77 14.92 11 14090 1946 90612400
Joint swelling 28.49 14.92 22 14079 503278 90111068
Hypoglycaemic seizure 28.25 14.92 8 14093 552 90613794
Carcinoid crisis 28.17 14.92 7 14094 291 90614055
Angina pectoris 27.19 14.92 32 14069 39128 90575218
Drug intolerance 26.05 14.92 19 14082 447572 90166774
Discomfort 24.96 14.92 6 14095 274329 90340017
Impaired healing 23.64 14.92 4 14097 234195 90380151
Dyspnoea exertional 23.31 14.92 41 14060 72247 90542099
Presbyopia 22.87 14.92 7 14094 633 90613713
Hypoglycaemia neonatal 22.78 14.92 8 14093 1114 90613232
Loss of personal independence in daily activities 22.68 14.92 59 14042 136046 90478300
Thirst decreased 22.29 14.92 6 14095 343 90614003
Type 1 diabetes mellitus 22.05 14.92 12 14089 4800 90609546
Productive cough 21.43 14.92 41 14060 77022 90537324
Metabolic acidosis 21.18 14.92 34 14067 55642 90558704
Muscle necrosis 20.97 14.92 7 14094 837 90613509
Helicobacter infection 20.56 14.92 5 14096 226845 90387501
Nasal congestion 20.33 14.92 42 14059 83372 90530974
Sleep disorder therapy 20.32 14.92 6 14095 480 90613866
Product dose omission issue 19.91 14.92 94 14007 291593 90322753
Depressed mood 19.55 14.92 31 14070 50191 90564155
Reperfusion arrhythmia 19.54 14.92 5 14096 234 90614112
Musculoskeletal stiffness 19.41 14.92 11 14090 296521 90317825
Diabetic nephropathy 19.39 14.92 8 14093 1726 90612620
Infective myositis 19.15 14.92 4 14097 75 90614271
Retinal degeneration 19.10 14.92 7 14094 1102 90613244
Analgesic therapy 18.40 14.92 6 14095 666 90613680
Abdominal discomfort 18.07 14.92 29 14072 477299 90137047
Drug ineffective 18.03 14.92 134 13967 1384164 89230182
Rheumatoid arthritis 17.91 14.92 18 14083 362596 90251750
Antacid therapy 17.73 14.92 6 14095 748 90613598
Anti-insulin antibody positive 17.69 14.92 4 14097 110 90614236
Appendicolith 17.67 14.92 6 14095 755 90613591
Incorrect dose administered by device 17.52 14.92 11 14090 5726 90608620
Tendon injury 17.37 14.92 8 14093 2245 90612101
Drug therapy 17.31 14.92 6 14095 803 90613543
Anticoagulant therapy 17.26 14.92 6 14095 811 90613535
Asthma 17.23 14.92 79 14022 242081 90372265
Therapeutic product effect decreased 17.18 14.92 11 14090 277560 90336786
Product prescribing error 16.70 14.92 22 14079 30123 90584223
Diabetic foot 16.48 14.92 7 14094 1624 90612722
Intestinal ulcer 16.28 14.92 7 14094 1672 90612674
Influenza 16.11 14.92 53 14048 139211 90475135
Inflammation 16.05 14.92 4 14097 178588 90435758
Haemorrhagic disorder 16.00 14.92 6 14095 1006 90613340
Palpitations 15.78 14.92 52 14049 136676 90477670
Injection site pain 15.73 14.92 61 14040 173638 90440708
Myopia 15.34 14.92 7 14094 1925 90612421
Insulin resistance 15.22 14.92 6 14095 1152 90613194
Erysipelas 15.12 14.92 12 14089 9040 90605306
Musculoskeletal pain 15.08 14.92 4 14097 171247 90443099
Pre-eclampsia 15.03 14.92 13 14088 11035 90603311

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 502.80 19.11 190 16029 13266 42591850
Hypoglycaemia 483.07 19.11 294 15925 59560 42545556
Appendicitis 434.07 19.11 193 16026 20420 42584696
Cardiogenic shock 358.26 19.11 202 16017 35438 42569678
Stress 305.53 19.11 197 16022 44015 42561101
Ascites 288.32 19.11 209 16010 56469 42548647
Ventricular fibrillation 268.64 19.11 158 16061 29965 42575151
Blood phosphorus increased 262.63 19.11 117 16102 12408 42592708
Abdominal distension 228.53 19.11 201 16018 71534 42533582
Blood glucose increased 194.72 19.11 186 16033 73513 42531603
Multiple organ dysfunction syndrome 184.19 19.11 205 16014 96830 42508286
Myasthenia gravis 182.65 19.11 99 16120 16038 42589078
Diabetic ketoacidosis 170.14 19.11 106 16113 22261 42582855
Hyponatraemia 168.38 19.11 200 16019 101262 42503854
Blood uric acid increased 166.60 19.11 92 16127 15455 42589661
General physical health deterioration 159.85 19.11 239 15980 151007 42454109
Hyperphosphataemia 150.55 19.11 81 16138 12923 42592193
Dry mouth 145.73 19.11 121 16098 39758 42565358
Blood cholesterol increased 136.65 19.11 99 16120 26642 42578474
Blood glucose decreased 127.74 19.11 75 16144 14144 42590972
Bacterial infection 119.71 19.11 93 16126 27786 42577330
Diabetes mellitus inadequate control 119.70 19.11 74 16145 15316 42589800
Hypophosphataemia 117.28 19.11 82 16137 20863 42584253
Sleep disorder therapy 115.07 19.11 55 16164 6839 42598277
Analgesic therapy 114.87 19.11 54 16165 6470 42598646
Iron deficiency 114.50 19.11 64 16155 10997 42594119
Neuralgia 113.27 19.11 87 16132 25560 42579556
Constipation 113.18 19.11 213 16006 162078 42443038
Incorrect route of product administration 112.97 19.11 85 16134 24220 42580896
Abdominal pain 110.01 19.11 231 15988 190240 42414876
Drug therapy 109.85 19.11 52 16167 6328 42598788
Vomiting 105.67 19.11 294 15925 289429 42315687
Sepsis 100.61 19.11 229 15990 199105 42406011
Hypoglycaemic unconsciousness 81.62 19.11 24 16195 760 42604356
Impaired gastric emptying 79.52 19.11 37 16182 4329 42600787
Swelling 73.02 19.11 97 16122 54788 42550328
Nausea 72.23 19.11 320 15899 396479 42208637
Glycosylated haemoglobin increased 64.06 19.11 47 16172 12877 42592239
Anticoagulant therapy 60.29 19.11 31 16188 4504 42600612
Euglycaemic diabetic ketoacidosis 59.25 19.11 33 16186 5627 42599489
Antacid therapy 59.14 19.11 31 16188 4686 42600430
Thrombosis 58.00 19.11 98 16121 68413 42536703
Activated partial thromboplastin time prolonged 57.51 19.11 48 16171 15855 42589261
Sleep disorder 56.42 19.11 80 16139 48015 42557101
Somnolence 56.03 19.11 148 16071 140957 42464159
Intentional product misuse 51.67 19.11 88 16131 61812 42543304
Bacteroides infection 50.48 19.11 23 16196 2564 42602552
Toxicity to various agents 49.62 19.11 13 16206 229123 42375993
Drug intolerance 47.97 19.11 99 16120 80325 42524791
Hyperglycaemia 46.17 19.11 71 16148 45788 42559328
End stage renal disease 45.92 19.11 43 16176 16515 42588601
Chronic obstructive pulmonary disease 45.30 19.11 84 16135 63030 42542086
Troponin increased 44.43 19.11 45 16174 19017 42586099
Aortic stenosis 43.78 19.11 32 16187 8713 42596403
Drug hypersensitivity 40.18 19.11 105 16114 99284 42505832
Ulcer 38.66 19.11 39 16180 16402 42588714
Hypoglycaemic encephalopathy 38.60 19.11 11 16208 311 42604805
Onychoclasis 37.79 19.11 19 16200 2633 42602483
Hypoglycaemia unawareness 36.25 19.11 9 16210 147 42604969
Hypoglycaemic seizure 36.21 19.11 11 16208 390 42604726
Total lung capacity decreased 35.16 19.11 20 16199 3550 42601566
Blood calcium increased 33.67 19.11 27 16192 8427 42596689
Disease progression 33.35 19.11 7 16212 143649 42461467
Hyperlipidaemia 33.27 19.11 41 16178 21475 42583641
Hypoglycaemic coma 31.48 19.11 17 16202 2727 42602389
Anion gap abnormal 31.14 19.11 10 16209 427 42604689
Bronchopulmonary aspergillosis allergic 30.49 19.11 20 16199 4578 42600538
Blood glucose fluctuation 28.12 19.11 19 16200 4568 42600548
Gout 27.62 19.11 43 16176 28012 42577104
Drug ineffective 27.59 19.11 135 16084 630062 41975054
Pulmonary embolism 27.56 19.11 104 16115 119508 42485608
Blood test abnormal 27.43 19.11 29 16190 12877 42592239
Henoch-Schonlein purpura nephritis 26.33 19.11 5 16214 20 42605096
Hypotension 26.09 19.11 36 16183 257595 42347521
Congenital hiatus hernia 25.19 19.11 20 16199 6154 42598962
Pneumonia 24.38 19.11 81 16138 422068 42183048
Neutropenia 24.34 19.11 24 16195 199407 42405709
Lung opacity 24.01 19.11 19 16200 5818 42599298
Pyrexia 23.87 19.11 74 16145 393968 42211148
Condition aggravated 23.13 19.11 174 16045 260580 42344536
Neuropathy peripheral 22.99 19.11 88 16131 101765 42503351
Diabetic neuropathy 21.47 19.11 16 16203 4486 42600630
Drug interaction 20.88 19.11 44 16175 266955 42338161
Tachycardia 19.57 19.11 7 16212 101080 42504036

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1097.54 14.60 547 26864 115557 110446331
Appendicolith 591.30 14.60 195 27216 14060 110547828
Diabetic ketoacidosis 499.12 14.60 232 27179 41826 110520062
Appendicitis 476.65 14.60 200 27211 28264 110533624
Blood glucose increased 422.42 14.60 311 27100 132185 110429703
Cardiogenic shock 365.06 14.60 208 27203 57130 110504758
Stress 355.47 14.60 256 27155 105092 110456796
Ventricular fibrillation 301.54 14.60 164 27247 41149 110520739
Blood phosphorus increased 301.16 14.60 123 27288 16217 110545671
Ascites 295.95 14.60 218 27193 92590 110469298
Diabetes mellitus inadequate control 250.59 14.60 130 27281 29645 110532243
Myasthenia gravis 219.43 14.60 107 27304 21404 110540484
Abdominal distension 199.26 14.60 231 27180 174872 110387016
Multiple organ dysfunction syndrome 196.29 14.60 214 27197 151496 110410392
Blood uric acid increased 192.72 14.60 98 27313 21431 110540457
Hyperphosphataemia 183.81 14.60 87 27324 16294 110545594
Blood glucose decreased 182.29 14.60 105 27306 29383 110532505
Hyperglycaemia 165.67 14.60 150 27261 84940 110476948
Sleep disorder therapy 154.09 14.60 61 27350 7410 110554478
Analgesic therapy 152.08 14.60 60 27351 7224 110554664
Hyponatraemia 146.52 14.60 222 27189 217431 110344457
Drug therapy 145.05 14.60 58 27353 7233 110554655
Impaired gastric emptying 138.28 14.60 67 27344 13208 110548680
Diabetic neuropathy 133.44 14.60 54 27357 6945 110554943
Iron deficiency 128.28 14.60 71 27340 18405 110543483
Hypoglycaemic coma 127.64 14.60 49 27362 5484 110556404
Hypophosphataemia 126.55 14.60 87 27324 33095 110528793
Blood glucose fluctuation 125.14 14.60 53 27358 7645 110554243
Glycosylated haemoglobin increased 124.78 14.60 76 27335 23543 110538345
Bacterial infection 124.29 14.60 98 27313 45938 110515950
Hypoglycaemic unconsciousness 122.18 14.60 33 27378 1187 110560701
Euglycaemic diabetic ketoacidosis 122.09 14.60 59 27352 11564 110550324
Neuralgia 119.83 14.60 98 27313 48380 110513508
Sepsis 118.70 14.60 255 27156 327091 110234797
Constipation 116.55 14.60 267 27144 357519 110204369
Heart sounds 91.80 14.60 26 27385 1117 110560771
Incorrect route of product administration 89.15 14.60 94 27317 63967 110497921
Anticoagulant therapy 87.44 14.60 37 27374 5324 110556564
Antacid therapy 86.63 14.60 37 27374 5447 110556441
Prolonged expiration 83.95 14.60 26 27385 1526 110560362
General physical health deterioration 79.67 14.60 259 27152 425036 110136852
Hypoglycaemic encephalopathy 79.52 14.60 21 27390 692 110561196
Hypoglycaemia unawareness 77.46 14.60 17 27394 249 110561639
Thrombosis 76.11 14.60 113 27298 108549 110453339
Diabetic retinopathy 73.15 14.60 29 27382 3535 110558353
Abdominal pain 72.64 14.60 285 27126 512704 110049184
Activated partial thromboplastin time prolonged 72.24 14.60 53 27358 22315 110539573
Infusion related reaction 66.86 14.60 8 27403 381154 110180734
Neuropathy peripheral 65.27 14.60 140 27271 179137 110382751
End stage renal disease 65.13 14.60 49 27362 21424 110540464
Aortic stenosis 63.83 14.60 40 27371 13019 110548869
Troponin increased 62.91 14.60 55 27356 29711 110532177
Bacteroides infection 57.29 14.60 23 27388 2896 110558992
Chronic obstructive pulmonary disease 56.57 14.60 99 27312 109059 110452829
Dry mouth 56.14 14.60 141 27270 199807 110362081
Vomiting 55.73 14.60 401 27010 910274 109651614
Toxicity to various agents 55.24 14.60 25 27386 480530 110081358
Ketoacidosis 54.66 14.60 33 27378 10054 110551834
Hyperlipidaemia 54.19 14.60 55 27356 35793 110526095
Synovitis 52.68 14.60 4 27407 274088 110287800
Intentional product misuse 52.10 14.60 107 27304 132797 110429091
Blood glucose abnormal 51.93 14.60 35 27376 12881 110549007
Gout 51.48 14.60 54 27357 36512 110525376
Hypoglycaemic seizure 51.38 14.60 16 27395 956 110560932
Arthropathy 50.50 14.60 6 27405 287516 110274372
Treatment failure 48.16 14.60 6 27405 277228 110284660
Appetite disorder 47.94 14.60 30 27381 9739 110552149
Somnolence 46.76 14.60 171 27240 297278 110264610
Joint swelling 46.45 14.60 26 27385 442819 110119069
Blood calcium increased 45.68 14.60 37 27374 18003 110543885
Nausea 45.27 14.60 486 26925 1235204 109326684
Scleroedema 44.92 14.60 10 27401 157 110561731
Diabetic metabolic decompensation 44.68 14.60 21 27390 3868 110558020
Diabetes mellitus 43.74 14.60 84 27327 99297 110462591
Total lung capacity decreased 43.07 14.60 25 27386 7089 110554799
Respiration abnormal 42.87 14.60 28 27383 9781 110552107
Sleep disorder due to a general medical condition 42.07 14.60 58 27353 52054 110509834
Depressive symptom 41.70 14.60 26 27385 8388 110553500
Rales 41.17 14.60 40 27371 24699 110537189
Therapeutic product effect decreased 38.51 14.60 7 27404 244309 110317579
Suicide attempt 37.90 14.60 81 27330 103313 110458575
Systemic lupus erythematosus 36.58 14.60 9 27402 254329 110307559
Drug ineffective 35.73 14.60 226 27185 1520314 109041574
Congenital hiatus hernia 35.27 14.60 21 27390 6238 110555650
Ulcer 33.32 14.60 47 27364 43069 110518819
Intentional overdose 32.63 14.60 89 27322 132412 110429476
Pulmonary embolism 32.59 14.60 122 27289 214352 110347536
Medical device site abscess 32.33 14.60 8 27403 202 110561686
Completed suicide 32.19 14.60 10 27401 242371 110319517
Bronchopulmonary aspergillosis allergic 31.90 14.60 22 27389 8404 110553484
Sinusitis 31.70 14.60 17 27394 296671 110265217
Inflammation 31.63 14.60 5 27406 193233 110368655
Medical device site cellulitis 31.58 14.60 8 27403 223 110561665
Rheumatoid arthritis 30.81 14.60 18 27393 299595 110262293
Joint abscess 30.70 14.60 10 27401 691 110561197
Fear-related avoidance of activities 30.39 14.60 7 27404 129 110561759
Discomfort 30.10 14.60 8 27403 214699 110347189
Lung opacity 29.72 14.60 24 27387 11628 110550260
Blood cholesterol increased 29.66 14.60 107 27304 184678 110377210
Anion gap abnormal 28.98 14.60 10 27401 826 110561062
Pancreatic carcinoma 28.49 14.60 26 27385 14846 110547042
Impaired healing 28.20 14.60 7 27404 196710 110365178
Drug abuse 28.13 14.60 5 27406 177406 110384482
Onychoclasis 27.64 14.60 19 27392 7218 110554670
Disease progression 27.54 14.60 13 27398 244021 110317867
Helicobacter infection 27.01 14.60 6 27405 181871 110380017
Liver injury 26.74 14.60 3 27408 150410 110411478
Blood test abnormal 26.45 14.60 34 27377 28520 110533368
Tachycardia 25.69 14.60 12 27399 226633 110335255
Intentional product use issue 25.33 14.60 15 27396 247891 110313997
Musculoskeletal pain 25.31 14.60 7 27404 183016 110378872
Neutropenia 24.76 14.60 34 27377 374586 110187302
Hypersensitivity 24.43 14.60 39 27372 403959 110157929
Pain 24.42 14.60 138 27273 954817 109607071
Diabetic foot 23.76 14.60 14 27397 4081 110557807
Arthralgia 23.13 14.60 107 27304 779525 109782363
Abdominal discomfort 22.90 14.60 39 27372 393819 110168069
Stomatitis 22.85 14.60 20 27391 270222 110291666
Wound 22.83 14.60 15 27396 234422 110327466
Fibromyalgia 22.78 14.60 7 27404 170902 110390986
Retinopathy 22.74 14.60 14 27397 4415 110557473
Contraindicated product administered 22.70 14.60 17 27394 248250 110313638
Hypoacusis 22.37 14.60 35 27376 35156 110526732
Oedematous pancreatitis 22.35 14.60 10 27401 1644 110560244
Thrombocytopenia 21.74 14.60 33 27378 348852 110213036
Alopecia 21.31 14.60 36 27375 364717 110197171
C-reactive protein increased 21.14 14.60 14 27397 217905 110343983
Hypotension 20.65 14.60 64 27347 523785 110038103
Carcinoid crisis 20.65 14.60 7 27404 548 110561340
Anti-insulin antibody positive 20.60 14.60 6 27405 285 110561603
Flank pain 20.58 14.60 27 27384 23103 110538785
Acute painful neuropathy of rapid glycaemic control 20.54 14.60 4 27407 31 110561857
Hepatic enzyme increased 20.33 14.60 30 27381 320862 110241026
Ill-defined disorder 19.90 14.60 7 27404 156846 110405042
Migraine 19.59 14.60 9 27402 171643 110390245
Sleep disorder 19.43 14.60 99 27312 198545 110363343
Thirst decreased 19.16 14.60 6 27405 365 110561523
Type 2 diabetes mellitus 19.15 14.60 10 27401 177222 110384666
Benign prostatic hyperplasia 18.95 14.60 23 27388 18211 110543677
Device failure 18.71 14.60 15 27396 7192 110554696
Ketosis 18.71 14.60 9 27402 1745 110560143
Blister 17.84 14.60 18 27393 227358 110334530
Diabetic foot infection 17.47 14.60 7 27404 877 110561011
Diabetic wound 17.40 14.60 4 27407 73 110561815
Psoriatic arthropathy 17.32 14.60 14 27397 196747 110365141
Incorrect dose administered by device 17.30 14.60 14 27397 6800 110555088
Therapy non-responder 16.81 14.60 9 27402 157298 110404590
Leukopenia 16.67 14.60 8 27403 148783 110413105
Hyperinsulinaemic hypoglycaemia 16.25 14.60 5 27406 287 110561601
Product use issue 16.22 14.60 33 27378 311662 110250226
White blood cell count decreased 15.99 14.60 20 27391 229370 110332518
Reperfusion arrhythmia 15.89 14.60 5 27406 309 110561579
Renal impairment 15.77 14.60 90 27321 188355 110373533
Pharyngeal perforation 15.68 14.60 3 27408 21 110561867
Contusion 15.59 14.60 21 27390 233340 110328548
Diabetic nephropathy 15.30 14.60 10 27401 3498 110558390
Presbyopia 15.12 14.60 6 27405 733 110561155
Dyspepsia 15.12 14.60 15 27396 190950 110370938
Nasal congestion 14.99 14.60 56 27355 98226 110463662
Micturition urgency 14.84 14.60 21 27390 19299 110542589

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10AD06 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
ATC A10AE06 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
ATC A10AE56 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
FDA CS M0011417 Insulin
FDA EPC N0000175453 Insulin Analog
FDA EPC N0000175944 Insulin
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35821 anticholesteremic drug
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:50864 insulin-sensitizing drug
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:73336 vulnerary
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:76916 hyperglycemic agent
CHEBI has role CHEBI:145947 antiatherosclerotic agent
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting 5 drugs
insulin aspartinsulin beefinsulin humaninsulin lisproinsulin pork
A10AE Insulins and analogues for injection, long-acting 9 drugs
insulin beefinsulin detemirinsulin glargineinsulin humaninsulin icodecinsulin porkliraglutidelixisenatidesemaglutide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus indication 73211009 DOID:9351




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Insulin receptor Kinase AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
D09727 KEGG_DRUG
4017559 VANDF
4017569 VANDF
4019786 VANDF
4035011 VANDF
CHEBI:752911 CHEBI
CHEMBL2107869 ChEMBL_ID
C571886 MESH_SUPPLEMENTAL_RECORD_UI
DB09564 DRUGBANK_ID
1670007 RXNORM
236826 MMSL
29260 MMSL
361472 MMSL
366445 MMSL
4885 MMSL
4886 MMSL
d00262 MMSL
d04369 MMSL
d08054 MMSL
000869 NDDF
000870 NDDF
006518 NDDF
015340 NDDF
126210001 SNOMEDCT_US
417423002 SNOMEDCT_US
420609005 SNOMEDCT_US
710281005 SNOMEDCT_US
715774000 SNOMEDCT_US
96367001 SNOMEDCT_US
C3491971 UMLSCUI
C0795635 UMLSCUI
DB00030 DRUGBANK_ID
9170 INN_ID
118984462 PUBCHEM_CID
118984375 PUBCHEM_CID
54Q18076QB UNII
5186 INN_ID
CHEBI:5931 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tresiba HUMAN PRESCRIPTION DRUG LABEL 1 0169-2550 INJECTION, SOLUTION 200 U SUBCUTANEOUS BLA 27 sections
Tresiba HUMAN PRESCRIPTION DRUG LABEL 1 0169-2660 INJECTION, SOLUTION 100 U SUBCUTANEOUS BLA 27 sections
Tresiba HUMAN PRESCRIPTION DRUG LABEL 1 0169-2662 INJECTION, SOLUTION 100 U SUBCUTANEOUS BLA 27 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 100 [iU] SUBCUTANEOUS BLA 27 sections
Tresiba HUMAN PRESCRIPTION DRUG LABEL 1 50090-3491 INJECTION, SOLUTION 200 U SUBCUTANEOUS BLA 28 sections
TRESIBA HUMAN PRESCRIPTION DRUG LABEL 1 50090-7094 INJECTION, SOLUTION 200 U SUBCUTANEOUS BLA 27 sections
Insulin Degludec HUMAN PRESCRIPTION DRUG LABEL 1 50090-7175 INJECTION, SOLUTION 200 U SUBCUTANEOUS BLA 27 sections
Insulin Degludec HUMAN PRESCRIPTION DRUG LABEL 1 50090-7176 INJECTION, SOLUTION 100 U SUBCUTANEOUS BLA 27 sections
Insulin Degludec HUMAN PRESCRIPTION DRUG LABEL 1 73070-400 INJECTION, SOLUTION 100 U SUBCUTANEOUS BLA 27 sections
Insulin Degludec HUMAN PRESCRIPTION DRUG LABEL 1 73070-403 INJECTION, SOLUTION 100 U SUBCUTANEOUS BLA 27 sections
Insulin Degludec HUMAN PRESCRIPTION DRUG LABEL 1 73070-503 INJECTION, SOLUTION 200 U SUBCUTANEOUS BLA 27 sections